Study: CBD Reduces Parkinson’s Treatment Side Effect Without Hindering Motor Benefits

Published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, the study investigated the effects of CBD and a fluorinated CBD derivative (PECS-101) on L-DOPA-induced dyskinesia (LID)—a frequent complication of prolonged dopamine replacement therapy in Parkinson’s Disease. Using a rat model with induced dyskinesia, researchers from the University of São Paulo found that both CBD and PECS-101 significantly reduced abnormal involuntary movements over a two-week treatment period. Importantly, the reduction in dyskinesia did not interfere with L-DOPA’s motor-enhancing effects. Mechanistically, CBD’s antidyskinetic effects were linked to interactions with CB1 and PPARγ receptors, and were enhanced when combined with a TRPV-1 antagonist (capsazepine) and a nitric oxide synthase inhibitor. The researchers also observed increased levels of endocannabinoids (anandamide and 2-AG) and a reduction in inflammatory markers in the brain and periphery.

The findings indicate that CBD could be a promising strategy to manage LID by modulating multiple receptor systems and reducing inflammation, while preserving the beneficial effects of L-DOPA.